HBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harvard Bioscience Inc (HBIO) does not present a compelling buy opportunity for a beginner investor with a long-term focus. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or news to drive momentum. While the price target was recently raised, the speculative nature of the rating and the company's declining revenue and net income make it unsuitable for a long-term, risk-averse investor.
The MACD is positive and expanding, indicating mild bullish momentum. RSI is neutral at 57.72, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 5.038, with resistance at 5.393 and support at 4.682. Overall, the technical indicators do not suggest a strong buy signal.
The MACD histogram is positive, and the gross margin increased by 8.07% YoY in the latest quarter. Additionally, the price target was raised to $6 by an analyst, reflecting some optimism.
The EPS remains negative at -0.
There is no recent news or significant trading activity from insiders, hedge funds, or Congress. The stock's implied volatility rank is very low at 0.06, and the options market shows minimal activity.
In Q4 2025, revenue dropped to $23.735M (-3.34% YoY), net income fell drastically to -$2.847M (-15916.67% YoY), and EPS remained negative at -0.64. However, gross margin improved to 56.13% (+8.07% YoY). Overall, the financial performance is weak, with declining growth metrics.
Benchmark analyst Bruce Jackson raised the price target to $6 from 60c after a 1:10 reverse split but maintained a speculative buy rating. Previously, the price target was lowered to 60c from $2, citing challenges in estimating recovery timing. The rating remains speculative, reflecting uncertainty in the company's outlook.
